Abstract
This chapter concerns the changing landscape of healthcare systems that are shifting towards an evidence-based paradigm. It discusses the process of health technology assessment and the use of real-world evidence (RWE) to inform coverage and reimbursement decisions. RWE is essential for sound coverage and payment decisions. Health technology assessment (HTA) is intended to capture the value of health improvement and provide evidence required to make informed decisions regarding coverage and payment decisions. The goal of HTA is to achieve value-based pricing for drugs and other healthcare services. In recent years, the inclusion of price negotiation has become part of the reimbursement decision-making process. Risk-sharing agreements between pharmaceutical companies and payers have been used broadly particularly for innovative medicines. In addition to the assessment of the comparative effectiveness and safety of a product, the evaluation of economic outcomes of cost-effectivenss based on RWE is another key element of HTA.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call